Moore Kuehn Encourages BIOT, VGII, CPTK, and DSAC Investors to Contact Law Firm
March 17, 2022 10:54 ET
|
Moore Kuehn
NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Moore Kuehn Encourages MNR, DSAC, BIOT, and ZIXI Investors to Contact Law Firm
November 11, 2021 10:15 ET
|
Moore Kuehn
NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
OnCore Biopharma Agrees to Acquire Enantigen Therapeutics
October 01, 2014 02:00 ET
|
OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Oct. 1, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biotechnology company focused on the research, development and commercialization of oral...